Insider Transactions in Q1 2022 at Allogene Therapeutics, Inc. (ALLO)
Insider Transaction List (Q1 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 31
2022
|
Pf Equity Holdings 2 B.V. > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
22,032,040
-100.0%
|
-
|
|
Mar 23
2022
|
Veer Bhavnagri General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
175,438
+22.94%
|
-
|
|
Mar 23
2022
|
Eric Thomas Schmidt Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
237,358
+41.26%
|
-
|
|
Mar 23
2022
|
Rafael Amado EVP of R&D |
BUY
Grant, award, or other acquisition
|
Direct |
237,358
+29.86%
|
-
|
|
Mar 15
2022
|
Alison Moore Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
8,698
-6.74%
|
$60,886
$7.63 P/Share
|
|
Mar 15
2022
|
Eric Thomas Schmidt Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
11,469
-10.24%
|
$80,283
$7.63 P/Share
|
|
Mar 15
2022
|
David D Chang President and CEO |
SELL
Open market or private sale
|
Direct |
23,648
-1.02%
|
$165,536
$7.65 P/Share
|
|
Mar 15
2022
|
Veer Bhavnagri General Counsel |
SELL
Open market or private sale
|
Direct |
8,849
-2.09%
|
$61,943
$7.68 P/Share
|
|
Mar 15
2022
|
Rafael Amado EVP of R&D |
SELL
Open market or private sale
|
Direct |
5,169
-1.59%
|
$36,183
$7.71 P/Share
|
|
Mar 14
2022
|
Arie Belldegrun Director |
BUY
Other acquisition or disposition
|
Indirect |
4,710,121
+50.0%
|
-
|
|
Mar 14
2022
|
Arie Belldegrun Director |
SELL
Other acquisition or disposition
|
Indirect |
4,710,121
-100.0%
|
-
|
|
Mar 07
2022
|
Joshua A Kazam |
SELL
Bona fide gift
|
Direct |
412,618
-61.45%
|
-
|
|
Mar 07
2022
|
Joshua A Kazam |
BUY
Other acquisition or disposition
|
Direct |
412,618
+38.06%
|
-
|
|
Jan 12
2022
|
Arie Belldegrun Director |
BUY
Open market or private purchase
|
Indirect |
155,039
+44.29%
|
$1,860,468
$12.6 P/Share
|
|
Jan 12
2022
|
Joshua A Kazam |
BUY
Open market or private purchase
|
Direct |
15,000
+5.48%
|
$180,000
$12.6 P/Share
|